New approach expected to increase use of technique in research and diagnosis Oxford, UK, September 8 2020 – ATDBio, a leader in complex oligonucleotide synthesis, and a research team at…
Read More
We are delighted to welcome two new organisations into Advanced Oxford’s membership. The Oxford Science Park and Carter Jonas have joined Advanced Oxford, as we continue to work to support…
Mon 3rd August 2020 Ground-breaking British technology will initially provide hundreds of thousands of fast, accurate, low-cost COVID-19 tests under new agreement with the UK Government, with the potential to…
Innovate UK grant to further development of ultrasound technology in back pain Data from extended Biomedical Catalyst award to support progression of OrthoSon technology towards first-in-human trial Oxford, UK, July…
Practical completion achieved for Bellhouse Building First tenants to move in to TOSP’s newest building by end of summer Oxford, UK, July 6 2020 – The Oxford Science Park (TOSP),…
Oxford, UK – 1st July 2020 – OxSonics Therapeutics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer today announced that a £10.5m Series B2 financing…
Oxford, UK, 1 July 2020 – The community of innovative companies at The Oxford Science Park, one of the UK’s leading parks for science and technology companies, is being enhanced…
Evox to use its proprietary exosome loading and CNS-targeting technologies to develop oligonucleotide drugs for the treatment of neurological disorders Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome…
Bergen, Norway – 02 June 2020: BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today announces that dosing has commenced…
IMC-F106C studied for the treatment of advanced cancers that express PRAME (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 26 May 2020) Immunocore (or the “Company”), a pioneering, clinical-stage T cell…
26th May 2020, Oxford, Copenhagen, and Hamburg – Exscientia, the world leading artificial intelligence (AI) drug discovery company, today announced it has raised $60 million in a Series C financing round….
Bergen, Norway, 5 May 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for unmet medical need, is pleased to announce that it has raised…
24 April 2020 Scancell Holdings plc (“Scancell” or the “Company”) Scancell to initiate development of novel DNA vaccine against COVID-19 Scancell Holdings plc, (AIM:SCLP), the developer of novel immunotherapies for…
Firms at The Oxford Science Park playing important role in COVID-19 response From immunology research tools and sequencing to AI and cloud telephony Oxford, UK, April 20 2020 – Several…
Exscientia announces joint initiative to identify COVID-19 drugs with Diamond Light Source and Scripps Research · Transatlantic partnership seeks to identify COVID-19 antiviral treatments · Exscientia to screen nearly…